Management of Health Crisis as a result of Earthquake in Province D.I. Yogyakarta and Central Java in Indonesia on May 27th, 2006
The use of the World Health Organization Health System Performance Assessment Framework
Contact No 175 - October December 2001
"This document has been developed for outpatient oncology
facilities to serve as a model for a basic infection
control and prevention plan. It contains policies
and procedures tailored to these settings to meet minimal
expectations of patient protections as described
in the CDC Guide to Infecti...on Prevention in Outpatient
Settings."
more
In the strategies for effective infection prevention and control (IPC), what does triage entail at hospitals?
Triage includes screening at the entrance, identification of cases and isolation if necessary. There should be a triage (screening) area where visitors to the hospital are interviewed using... standard questionnaires to identify symptoms, along with temperature checks and documentation of contacts. Individuals who meet the case definition for COVID-19 should be isolated immediately while arrangement is being made for swab (sample) collection from the patient. (See the WHO guidance on triage).
more
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more